Clinical Trials · NCT07097259
A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Enrollment
- 55
- Start date
- Jul 2025
- Locations
- 1 site, United States
- Primary endpoint
- Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Sampling Time After Administration (AUC0-t, adj) of Follitropin Alfa